New Hampshire Senate Bill SB256

New Hampshire 2025 Regular Session

• Introduced: 1/23/25
• Refer: 1/23/25
• Refer: 2/21/25
• Refer: 3/6/25

Caption

Relative to the affordability and safety of clinician administered drugs.

Summary

SB 256 would add a new section to New Hampshire law governing health maintenance organizations and the dispensing of clinician-administered drugs. The bill defines a “clinician-administered drug” as an outpatient prescription drug, other than a vaccine, that cannot reasonably be self-administered and is typically given by a health care professional in a clinical setting such as a physician’s office or hospital outpatient infusion center. The bill requires HMOs, and third parties acting for them, to cover a clinician-administered drug dispensed by an in-network hospital or clinic when medical standards indicate the medication must be provided more quickly than it could be obtained through another covered channel, and when the dispensing is consistent with the plan’s terms for similarly situated network participants. It also prohibits HMOs, pharmacy benefit managers, and other third parties from requiring, by contract or policy, that a pharmacy dispense such a drug directly to a patient for the patient to transport to a clinical setting, unless the patient or prescriber requests that arrangement in writing.

Impact

SB 256 would amend RSA 420-B by creating a new HMO-specific rule for clinician-administered drugs and limiting insurer and pharmacy benefit manager practices commonly referred to as “brown-bagging.” In practical terms, it would restrict health plans from steering these drugs through a patient pick-up model and would instead support direct dispensing to in-network hospitals or clinics when clinically necessary and faster. The bill applies to HMOs rather than all insurers, and it would take effect January 1, 2026.

Sentiment

The available materials suggest the bill is framed as a consumer-access and patient-safety measure, with sponsors emphasizing affordability and safer administration of drugs that are meant to be given by professionals. The fiscal note also reflects a neutral, technical posture, noting no direct state spending but possible indeterminate revenue effects if premiums rise. No committee transcript or vote record is provided, so there is no documented opposition or recorded floor sentiment in the supplied materials.

Contention

The main policy tension is between lowering costs through patient-mediated dispensing and avoiding the risks and delays associated with brown-bagging. Supporters appear to favor direct dispensing in clinical settings for drugs that should not be self-administered, while the Insurance Department notes that prohibiting brown-bagging could increase insurer costs and potentially premiums, which could affect insurance premium tax revenue. Another point of scope is that the bill reaches HMOs and their agents, but not other types of insurers, which may limit its effect and could be a point of debate.